Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:INO

Inovio Pharmaceuticals Q3 2026 Earnings Date & Estimates

Inovio Pharmaceuticals logo
$1.01 +0.01 (+1.00%)
Closing price 10/20/2026 04:00 PM Eastern
Extended Trading
$1.06 +0.04 (+4.46%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inovio Pharmaceuticals is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. The conference call is scheduled for November 9, 2026 at 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Inovio Pharmaceuticals in Q3 2026

Inovio Pharmaceuticals is expected to post earnings of -$0.20 per share on revenue of $2.27 million. In the same quarter a year earlier Inovio Pharmaceuticals reported -$0.44 per share. Inovio Pharmaceuticals last reported on August 12, 2026, posting -$0.07 per share and beating the -$0.2167 consensus estimate. Inovio Pharmaceuticals has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.20
Expected Revenue
$2.27 million
Prior-Year EPS
-$0.44

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.07 (Beat by +$0.1467)
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Inovio Pharmaceuticals Q3 2026 Earnings FAQ

Inovio Pharmaceuticals (NASDAQ:INO) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Inovio Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Inovio Pharmaceuticals to post earnings of -$0.20 per share for Q3 2026.

The consensus revenue estimate for Inovio Pharmaceuticals is $2.27 million for Q3 2026.

Inovio Pharmaceuticals Earnings Headlines

Inovio Says it Secured Favorable Judgment in VGXI, GeneOne Litigation
October 20 at 11:43 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/inovio-says-secured-favorable-judgment-214458586.html
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
October 20 at 4:05 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/inovio-announces-favorable-judgment-in-litigation-with-vgxi-inc-and-geneone-life-science-302914515.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
FDA decision watch: What investors need to know about four upcoming drug rulings
October 19 at 7:16 AM  |  msn.comhttps://www.msn.com/en-in/news/other/fda-decision-watch-what-investors-need-to-know-about-four-upcoming-drug-rulings/ar-AA2fzDoY
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-backs-pfes-tukysa-combo-144500683.html
Inovio Updates Bylaws with New Exclusive-Forum Provision
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inovio-updates-bylaws-with-new-exclusive-forum-provision?utm_source=marketbeat.com&utm_medium=referral
See More Inovio Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inovio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inovio Pharmaceuticals and other key companies, straight to your email.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals (NASDAQ:INO) (NASDAQ: INO) is a biotechnology company focused on developing DNA medicines, including immunotherapies and vaccines designed to stimulate targeted immune responses. Its technology platform uses synthetic DNA constructs delivered into cells, with the company’s CELLECTRA device platform developed to enhance cellular uptake.

Inovio’s pipeline has included candidates for infectious diseases, cancers and other conditions involving the immune system. Its lead programs have included INO-3107, an investigational DNA immunotherapy being developed for recurrent respiratory papillomatosis, and VGX-3100, an earlier candidate studied for human papillomavirus-related disease. The company’s programs remain subject to clinical testing and regulatory review, and its products are not necessarily approved or commercially available.

Founded in the United States, Inovio has conducted research and clinical development activities in collaboration with academic institutions, government agencies and biotechnology partners in the U.S. and internationally. The company is headquartered in Plymouth Meeting, Pennsylvania, and is led by President and Chief Executive Officer Jacqueline Shea.

View Inovio Pharmaceuticals Profile
Earnings Tools